
    
      The study population was chosen from a non-probability sample.

      The safety population consisted of all participants with at least one documented infusion of
      infliximab.

      The evaluable population consisted of all participants that were >=18 years of age with a
      recorded indication for infliximab use, that had available baseline data, and with at least 3
      infusions of infliximab within the first 16 weeks of the study. Baseline characteristics are
      provided for this population.
    
  